Click here to stream the public defence
Due to copyright issues, an electronic copy of the thesis must be ordered from the faculty. For the faculty to have time to process the order, the order must be received by the faculty at the latest 2 days before the public defence. Orders received later than 2 days before the defence will not be processed. After the public defence, please address any inquiries regarding the thesis to the candidate.
Trial Lecture – time and place
See Trial Lecture.
Adjudication committee
- First opponent: Clinical Senior Lecturer Channa Jayasena, Imperial College and Hammersmith Hospital London, UK
- Second opponent: Associate Professor Henrik Horwitz, Bispebjerg Hospital and University of Copenhagen, Denmark
- Third member and chair of the evaluation committee: Associate Professor Gudrun Høiseth, University of Oslo
Chair of the Defence
Professor II Børre Fevang, University of Oslo
Principal Supervisor
Associate Professor Ingrid Amalia Havnes, University of Oslo
Summary
The use of anabolic-androgenic steroids (AAS) leads to several adverse health effects, including cardiovascular disease and a dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis. The subsequent decrease in endogenous testosterone production following AAS cessation, termed AAS-induced hypogonadism (ASIH), manifests as symptoms that include fatigue, depression, anxiety and sexual dysfunction.
Despite experiencing ASIH or other side effects from use, individuals using AAS often exhibit reluctance to seek treatment. Reluctance to seek health services is largely attributed to the absence of treatment guidelines and clinicians' lack of confidence in addressing ASIH.
This thesis aims to enhance treatment knowledge for people with AAS use by a two-fold approach: First, by examining the association between health service engagement and AAS-related health issues, and second, by assessing an off-label hormone intervention with clomiphene citrate and optional human chorionic gonadotropin for AAS-dependent men struggling with ASIH, aiming to discontinue long-term AAS use.
Findings revealed that those seeking healthcare experienced more AAS-related side effects, although most had never sought treatment despite having established cardiovascular disease.
Barriers to seeking treatment or participation in intervention studies included neglecting the severity of side effects, fear of legal consequences, and dissatisfaction with Norwegian public healthcare.
The hormone intervention appeared safe, showing a generally positive response in the HPG axis. However, only half of the participants achieved physiological testosterone levels, which did not correlate with withdrawal symptom severity.
The study highlights the complex nature of AAS dependence and the varied treatment needs in this population. It may guide future randomized clinical trials, ultimately leading to the development of new treatment guidelines for people with AAS use.
Additional information
Contact the research support staff.